What is CKD Bio Corp.'s (063160.KS) StockRank?

MoatMap's StockRank for CKD Bio Corp. (063160.KS) is 15/100, with a Strong Sell signal. This is a composite score combining Quality (38), Value (40), and Momentum (24) factor ranks across MoatMap's 20,000+ stock universe.

Does CKD Bio Corp. have an economic moat?

CKD Bio Corp. (063160.KS) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is CKD Bio Corp. a buy, hold, or sell?

MoatMap's current signal for CKD Bio Corp. (063160.KS) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is CKD Bio Corp. in?

CKD Bio Corp. (063160.KS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

063160.KS

STRONG SELLREMOVE

CKD Bio Corp. · Healthcare · South Korea · $62M · Avg Vol: $742K/d

StockRank

P/E (TTM)

—

ROE

5.6%

D/E

1.2x

Dividend %

0.5%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

CKD Bio Corp produces pharmaceutical ingredients but lacks the scale, regulatory moat, and high-utilization profile of the tier-1 CDMOs that we target for our pricing power theme.

COMPANY DESCRIPTION

CKD Bio Corp. specializes in the fermentation and manufacture of active pharmaceutical ingredients (APIs), with a focus on beta-lactamase inhibitors and probiotics. The company is a global market leader in the production of potassium clavulanate, an essential ingredient used to prevent antibiotic resistance. It operates as a highly specialized biotech manufacturer, leveraging advanced fermentation technologies and maintaining strict compliance with global regulatory standards to export to over 30 countries.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	103M	106M	113M	105M	0.9%
EPS	-2.00	-2.90	1.04	-0.35	—
Shares	5M	5M	5M	5M	-0.0%
Debt	91M	97M	86M	95M	1.4%
Equity	97M	81M	86M	84M	-4.9%
Op CF	-2M	-5M	9M	-3M	—
Inv CF	-14M	-786,994	-3M	-5M	—
Fin CF	16M	5M	-8M	8M	—

PRICE (1M)-15.4%

SMA 50SMA 200

$10.61

RSI (14)

30.1

52W High

$18.20

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

1.8%47.9

ROE

5.6%57.4

GP/Assets

8.0%23.1

Op. Margin

-13.4%28.0

FCF/Assets

-5.8%34.4

Piotroski

—55.7

Int. Cover

0.5x40.4

D/E Ratio

1.21x11.6

Current Ratio

2.69x48.8

Value

P/E (TTM)

—N/A

EV/EBITDA

13.6x31.1

P/FCF

—N/A

P/B

0.7x87.2

P/S

0.7x89.1

Div Yield

0.5%14.8

Momentum

52W High %

58%36.8

RS 6M

-144%4.2

SMA 50/200

0.88x29.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$62M

P/E (Forward)

—

Gross Margin

19.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 063160.KS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
063160.KS	CKD Bio Corp.(you)	$62M	15	STRONG SELL
032300.KQ	KOREA PHARMA Co., Ltd.	$63M	12	STRONG SELL
002390.KS	HANDOK Inc.	$73M	17	STRONG SELL
183490.KQ	Enzychem Lifesciences Corporation	$55M	18	STRONG SELL
092040.KQ	Amicogen, Inc.	$58M	7	STRONG SELL
000520.KS	Samil Pharmaceutical Co.,Ltd	$105M	14	STRONG SELL
058820.KQ	CMG Pharmaceutical Co., Ltd.	$107M	14	STRONG SELL
293780.KQ	AptaBio Therapeutics Inc.	$91M	3	STRONG SELL
256840.KQ	BNC KOREA, Inc.	$131M	19	STRONG SELL
214390.KS	Kyongbo Pharmaceutical Co., Ltd	$91M	27	SELL

Peer medians: ROE -1.3% · P/E 17.7x · Gross margin 43.6%

CKD Bio Corp. (063160.KS) — Stock Score Summary

CKD Bio Corp. (063160.KS) has a MoatMap StockRank of 15/100 based on Quality (38/100), Value (40/100), and Momentum (24/100) factor scores. The current signal is STRONG SELL. CKD Bio Corp produces pharmaceutical ingredients but lacks the scale, regulatory moat, and high-utilization profile of the tier-1 CDMOs that we target for our pricing power theme.

Key Financial Metrics

Price	$10.61
Market Cap	$62M
Price/Book	0.67
Return on Equity	5.6%
Return on Invested Capital	1.8%
Debt/Equity	120.93
Gross Margin	19.9%
Operating Margin	-13.4%
Revenue Growth	12.6%
Dividend Yield	0.5%
Free Cash Flow	$-8K

CKD Bio Corp. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is CKD Bio Corp.’s (063160.KS) StockRank?: MoatMap’s StockRank for CKD Bio Corp. (063160.KS) is 15/100, with a Strong Sell signal. It is a composite of Quality (38), Value (40), and Momentum (24) factor ranks across MoatMap’s 20,000+ stock universe.
Does CKD Bio Corp. have an economic moat?: CKD Bio Corp. (063160.KS) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is CKD Bio Corp. a buy, hold, or sell?: MoatMap’s current signal for CKD Bio Corp. (063160.KS) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is CKD Bio Corp. in?: CKD Bio Corp. (063160.KS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).